Loading…
← CockpitCompetitor Analysis › 3391.T TSURUHA Holdings, Inc.Open in the cockpit ↗

TSURUHA Holdings, Inc.3391.TCompetitor analysis, valuation and peers

Japan · JPY·Consumer Staples›Drugstore Chains

Operates a nationwide Japanese drugstore chain selling cosmetics, pharmacy and daily goods.

≈ Japan's WalgreensMomentum leader 84
Mkt cap
$7.15B
US dollars, full cap
Free float
45%
of shares outstanding
$/day
$32.2M
20-day average traded
Fwd P/E
23.8×
forward earnings
ROIC−WACC
+1.2 pp
WACC 5.0%
Hurdle
-11 pp
Req g minus delivered
Next earnings
127 days
25 Mar 2027
Close · JPY¥2,470
1D-2.6%
1W+0.6%
1M+11.2%
3M+2.7%
6M+17.2%
YTD-14.2%
1Y-8.2%
ATR %3.1%
52w lowhigh17.5% off high

What TSURUHA does

Operates a nationwide Japanese drugstore chain selling cosmetics, pharmacy and daily goods.

Sells cosmetics, health goods, groceries and medicines in store, where daily-use items and beauty bring in most sales and dispensing prescriptions adds steady fees. It began in Hokkaido and has grown by opening stores and buying regional chains.

In one line: Japan's Walgreens.

Products and services

  • Drugstore retail
  • Pharmacy/OTC medicine
  • Cosmetics/beauty counters

Customers

  • Domestic consumers
  • Inbound tourists (cosmetics)

Where it sits in the supply chain

  • Retail
  • Drugstore chain operation
  • Cosmetics, OTC drugs, daily goods…

What could go right

  • Inbound tourist cosmetics demand
  • Store consolidation/M&A

What could go wrong

  • Drugstore price competition

Moat: narrow (scale, distribution). Nationwide store scale gives purchasing power versus smaller regional drugstore chains.

Headquarters: Sapporo, Japan · Founded: 1929 · Employees: 27,681

Named competitors

TSURUHA at a glance

Size TSURUHA (3391.T) is a Japan Consumer Staples company (Drugstore Chains) with a market value of $7.15B, the 185th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,470 on 18 Nov 2026.

Performance Over six months the shares gained 17.2%, against +13.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 3rd highest of 7 in its peer set.

Growth Revenue grew 114.1% over the last twelve months (peer median +5.5%); the operating margin is 4.1% (peer median 6.9%).

Valuation It trades at 23.8× forward earnings against a peer median of 17.6× (2nd most expensive of 7).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -11 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.2 points above its cost of capital (5.0% WACC).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

10011012013021 May 202621 Aug 202618 Nov 20263391.T 122Peer median 118
Six months, rebased to 100: TSURUHA against the median of its 6 peers (local-currency closes).

TSURUHA financials

Reported figures in JPY; fiscal year ends 2026-02-28. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥2.17T¥1.45T¥1.07T¥1.03T¥970B
Revenue growth—+35%+4%+6%—
Gross profit¥669B¥444B¥326B¥312B¥293B
EBITDA¥142B¥93.7B¥67.6B¥67.2B¥62.1B
Net income¥52.6B¥42.7B¥21.8B¥24.1B¥25.3B
Free cash flown/a¥59.7B¥44.5B¥20.0B-¥23.9B
Capital expendituren/a¥28.5B¥22.8B¥35.4B¥26.7B
Total debt¥201B¥208B¥63.8B¥50.0B¥54.9B

Quarterly statements and history in the cockpit →

TSURUHA competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-10%0%+10%+20%+30%+5%+10%+15%30886039396032337649GRDN99893391.T6-month return →1-month return →
Up and to the right = strong over both horizons. TSURUHA is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×30×3088603939603233GRDN99893391.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. TSURUHA is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%-10%0%10%30886039396032337649GRDN99893391.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. TSURUHA is the large dot.

TSURUHA competitors and peer comparison

Head to head with its named competitors (3391.T vs 3088.T vs 7649.T vs 3349.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
TSURUHA 3391.T$7.15B+17%+114%4%23.8×-1.5%
MatsukiyoCocokara & 3088.T$7.51B+29%+6%8%19.5×-4.8%
Sugi 7649.T$3.46B-9%+9%5%17.9×-9.0%
COSMOS Pharmaceutical 3349.T$3.21B+2%+9%4%15.9×n/a
Kusuri No Aoki 3549.T$2.98B+29%+13%5%22.2×4.3%
Sundrug 9989.T$3.07B+10%+4%6%14.9×-7.3%
Create SD 3148.T$1.32B+3%+9%5%n/a-11.5%

How TSURUHA compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

TSURUHA against its 6 peers (data as of 18 Nov 2026)
Measure3391.TPeer medianRank in peer set
1-month return+11.2%+13.5%3rd lowest of 7
6-month return+17.2%+13.1%3rd highest of 7
Distance from 52-week high-17.5%-4.4%2nd lowest of 7
Revenue growth (TTM)+114.1%+5.5%highest of 7
Operating margin4.1%6.9%lowest of 7
Forward P/E23.8×17.6×2nd most expensive of 7
Growth the price implies (Req g, 7 yrs)-1.5%-8.2%2nd most demanding of 7
Growth delivered (Del g)+9.6%+13.4%2nd lowest of 7
Hurdle (Req g minus delivered)-11.0 pp-20.1 ppmost demanding of 7
ROIC minus cost of capital+1.2 pp+10.2 pplowest of 7
EV / EBITDA8.6×8.7×3rd cheapest of 5
Net debt / EBITDA0.4×-0.6×most indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
TSURUHA 3391.TJapan$7.15B+17%+114%4%23.8×-1.5%+9.6%
MatsukiyoCocokara & 3088.TJapan$7.51B+29%+6%8%19.5×-4.8%+15.5%
Yifeng Pharmacy Chain 603939.SSChina$4.84B+16%+5%10%17.2×-9.3%+13.2%
DaShenLin Pharmaceutical 603233.SSChina$3.64B+10%+7%8%15.9×-9.5%+13.6%
Sugi 7649.TJapan$3.46B-9%+9%5%17.9×-9.0%+10.9%
Guardian Pharmacy Services GRDNUnited States$3.09B+30%+5%6%33.3×4.4%+16.8%
Sundrug 9989.TJapan$3.07B+10%+4%6%14.9×-7.3%+5.8%

Questions

Who are TSURUHA's main competitors?
Named competitors: MatsukiyoCocokara (3088.T), Welcia Holdings (private or unlisted), Sugi Holdings (7649.T), Cosmos Pharmaceutical (3349.T), Kusuri no Aoki Holdings (3549.T), Sundrug (9989.T). The cockpit's measured peer set (industry) also includes MatsukiyoCocokara & (3088.T), Yifeng Pharmacy Chain (603939.SS), DaShenLin Pharmaceutical (603233.SS), Sugi (7649.T), Guardian Pharmacy Services (GRDN), Sundrug (9989.T).
Is TSURUHA expensive compared with its peers?
On forward p/e it trades at 23.8× against a peer median of 17.6×, 2nd most expensive of 7 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -11 pp: the price already allows for a slowdown.
How has TSURUHA stock performed?
Over six months to 18 Nov 2026 the shares returned +17.2% against +13.1% for the median peer; over one year -8.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.